Real‐life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID‐19 pneumonia-Reference-Cited by-同舟云学术

Real‐life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID‐19 pneumonia

Published:2021-07-04 Issue:12 Volume:87 Page:4861-4867
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Corcione Silvia¹²^ORCID,De Nicolò Amedeo³,Montrucchio Giorgia⁴,Scabini Silvia¹,Avataneo Valeria³,Bonetto Chiara⁴,Mornese Pinna Simone¹,Cusato Jessica³,Canta Francesca¹,Urbino Rosario⁴,Di Perri Giovanni¹,Brazzi Luca⁴,De Rosa Francesco Giuseppe¹,D'Avolio Antonio³^ORCID

Affiliation:

1. Department of Medical Sciences, Infectious Diseases University of Turin Italy

2. Tufts School of Medicine Boston MA USA

3. Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital, Department of Medical Sciences University of Turin Italy

4. Department of Surgical Sciences University of Turin Italy

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14895

Reference28 articles.

1. 2019 novel coronavirus (2019-nCoV) outbreak: A new challenge

2. Veno-venous Extracorporeal Membrane Oxygenation for Respiratory Failure in COVID-19 Patients

3. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry

4. COVID‐19 Treatment Guidelines Panel.Coronavirus Disease 2019 (COVID‐19) Treatment Guidelines. National Institutes of Health. Available athttps://www.covid19treatmentguidelines.nih.gov/. Accessed May 20 2021.

5. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. Accessed May 20 2021.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiviral properties of milk proteins and peptides against SARS-COV-2: A review;Journal of Functional Foods;2024-06

2. Phylogenetic meta-analysis of chronic SARS-CoV-2 infections in immunocompromised patients shows no evidence of elevated evolutionary rates;2023-11-02

3. Population pharmacokinetics and exposure–clinical outcome relationship of remdesivir major metabolite GS‐441524 in patients with moderate and severe COVID‐19;CPT: Pharmacometrics & Systems Pharmacology;2023-02-22

4. Interpatient variability in the pharmacokinetics of remdesivir and its main metabolite GS-441524 in treated COVID-19 subjects;Journal of Antimicrobial Chemotherapy;2022-07-15

5. Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients;Antimicrobial Agents and Chemotherapy;2022-06-21